[The clinico-laboratory assessment of the efficacy of dalargin in treating acute suppurative-inflammatory processes of the maxillofacial area].
The data obtained by the authors provide evidence on dalargin effect on immune condition of patients with pyoinfammation of maxillofacial soft tissues. Dalargin administration leads to a rise in T-sensitive lymphocyte subpopulation in all the patients as well as stimulates functional activity of peripheral blood polymorphonuclear neutrophils. Similar results were obtained in vitro with dalargin addition to leukocytic suspension despite the absence of the drug bactericidal activity.
Bazhanov
N N
NN
Ganina
S S
SS
Pashutin
S B
SB
Ragimov
Ch R
ChR
D000208:Acute Disease; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D002481:Cellulitis / Q000188:drug therapy* / Q000276:immunology; D003131:Combined Modality Therapy; D016308:Enkephalin, Leucine-2-Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005145:Face; D005491:Focal Infection, Dental / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D007571:Jaw Diseases / Q000188:drug therapy* / Q000276:immunology
D000276:Adjuvants, Immunologic; D016308:Enkephalin, Leucine-2-Alanine; C040996:enkephalin-Leu, Ala(2)-Arg(6)-
Kliniko-laboratornaia otsenka éffektivnosti dalargina pri lechenii ostrykh gnoĭno-vospalitel'nykh protsessov cheliustno-litsevoĭ oblasti.